Binds Microorganism Or Normal Or Mutant Component Or Product Thereof (e.g., Animal Cell, Cell-surface Antigen, Secretory Product, Etc.) Patents (Class 530/388.2)
  • Publication number: 20130323751
    Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal to recovery and/or renal non-recovery.
    Type: Application
    Filed: January 20, 2012
    Publication date: December 5, 2013
    Applicant: University of Pittsburgh - of the Common-Wealth System of Higher Education
    Inventors: Kai Singbartl, John A. Kellum, JR.
  • Publication number: 20130317201
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.
    Type: Application
    Filed: October 28, 2011
    Publication date: November 28, 2013
    Applicant: PERSEUS PROTEOMICS INC.
    Inventors: Keisuke Ishii, Keiko Katsumi, Tadashi Matsuura, Yukio Sudo, Katsuyuki Mitomo, Katsushi Kouda
  • Publication number: 20130316384
    Abstract: The present disclosure provides ICE-cleaved alpha-synuclein fragments as biomarkers for alpha-synuclein-associated disease or disorder and/or for ICE-regulator therapy.
    Type: Application
    Filed: November 4, 2011
    Publication date: November 28, 2013
    Inventors: Dagmar Ringe, Gregory A. Petsko
  • Publication number: 20130316372
    Abstract: A method of differentiating oncogenic changes of the thyroid encompassing follicular adenoma and follicular cancer, characterised in that in a sample of oncogenic tissue from a patient the expression of the metallothionein (MT) potein is evaluated using immunochistochemical methods using monoclonal anti-MT antibodies, the degree of intensity of the expression of metallothionein is evaluated under a light microscope using the semiquantitative IRS method according to Remmele, wherein if the degree of intensity of the expression of metallothionein is equal to or greater than 8 on the semiquantitative IRS scale then the presence of follicular cancer is indicated.
    Type: Application
    Filed: December 21, 2011
    Publication date: November 28, 2013
    Applicant: Wroclawskie Centrum Badan EIT+Sp. z o.o.
    Inventors: Piotr Dziegiel, Marzena Podhorska-okolów, Anna Królicka, Christopher Kobierzycki, Bartosz Pula, Aleksandra Piotrowska
  • Patent number: 8591900
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: November 26, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
  • Patent number: 8591902
    Abstract: In order to identify a factor demonstrating a repellent effect on axon extension of a neuron, lysophosphatidylglucoside (LPG) has been found to have an activity as a chemorepellent effect on axon guidance of a DRG sensory neuron specific to a neuron expressing TrkA, an NGF receptor. In addition, it has been found out that suppressing the function of LPG makes it possible to suppress a repellent effect of LPG on axon extension of a neuron expressing TrkA. A molecule capable of suppressing the function of LPG can be a composition promoting repairing of a neural circuit in neuronal damages and the like.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: November 26, 2013
    Assignee: Riken
    Inventors: Yoshio Hirabayashi, Hiroyuki Kamiguchi, Kunihiro Ohta, Akiho Nakamura
  • Publication number: 20130309250
    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
    Type: Application
    Filed: May 13, 2013
    Publication date: November 21, 2013
    Inventors: John Cogswell, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi Tao Wang, John M. Wigginton
  • Publication number: 20130295095
    Abstract: The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated A? starting with pyroglutamate (A??E), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing A? oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056.
    Type: Application
    Filed: June 3, 2011
    Publication date: November 7, 2013
    Inventors: Thomas Bayer, Oliver Wirths, Henrik Martens, Christian Erck
  • Patent number: 8568725
    Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.
    Type: Grant
    Filed: December 24, 2004
    Date of Patent: October 29, 2013
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Nobuaki Takahashi, Toru Miura, Yoshinori Kitagawa, Aki Hirano
  • Publication number: 20130274449
    Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 17, 2013
    Inventors: Ernest S. SMITH, Terrence Lee Fisher
  • Publication number: 20130266584
    Abstract: The invention features the treatment of gastrointestinal disorders associated with an innate immune response tiggered by alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or alpha amylase inhibitor 0.53 (0.53). To this end, the invention features pharmaceutical compositions including neutralizing antibodies to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53, food products containing reduced levels of CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 protein, the use of oral TLR4 inhibitors to block the effect of said alpha-amylase inhibitors, assays for identifying CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 content in food products, and assays for diagnosing subjects with a disorder related to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 triggered innate immune responses.
    Type: Application
    Filed: April 29, 2011
    Publication date: October 10, 2013
    Inventors: Detlef Schuppan, Yvonne Junker, Towia Libermann, Simon T. Dillon
  • Publication number: 20130267687
    Abstract: Monoclonal antibodies, or fragments thereof, are used for isolating and/or identifying at least one cell population. The cell population can include any of the following types of cells: haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells. The antibodies, or fragments thereof, bind to an antigen which is the same as that bound by an antibody which is produced by the hybridoma cell lines CUB1, CUB2, CUB3 and CUB4, which were deposited in the DSMZ under the numbers DSM ACC2569, DSM ACC2566 and DSM ACC2565, on Aug. 14, 2002, and DSM ACC2551, on Jul. 12, 2002.
    Type: Application
    Filed: April 23, 2013
    Publication date: October 10, 2013
    Applicant: HOFFMAN-LA ROCHE INC.
    Inventors: HANS-JOERG BUEHRING, REINER LAMMERS, SELIM KUCI, TIM CONZE
  • Patent number: 8551485
    Abstract: The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: October 8, 2013
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, Eugene Alexander Zhukovsky
  • Publication number: 20130259872
    Abstract: An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFN?. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFN?.
    Type: Application
    Filed: June 7, 2013
    Publication date: October 3, 2013
    Inventors: Yumiko Kamogawa, Minkwon Cho, Naoko Arai, Koji Ishida
  • Patent number: 8545848
    Abstract: The invention relates to neutralizing antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalized B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 1, 2013
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonia Lanzavecchia, Annalisa Macagno
  • Publication number: 20130245230
    Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.
    Type: Application
    Filed: March 6, 2013
    Publication date: September 19, 2013
    Applicant: The Scripps Research Institute
    Inventors: Alexander Dieters, T. Ashton Cropp, Jason W. Chin, J. Christopher Anderson, Peter G. Schultz
  • Patent number: 8536312
    Abstract: The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The inventive monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: September 17, 2013
    Assignee: Adnagen GmbH
    Inventors: Christiane Hollmann, Silke Zimmermann, Stefan Stachelhaus, Winfried Albert
  • Publication number: 20130236451
    Abstract: Antibodies directed to the C-terminal side of ?-amyloid peptide and methods of using these antibodies for diagnosing and treatment of Alzheimer's disease and A? peptide associated diseases are described.
    Type: Application
    Filed: February 14, 2013
    Publication date: September 12, 2013
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventors: Arnon ROSENTHAL, Jaume PONS, Wei-Hsien HO
  • Publication number: 20130232589
    Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
    Type: Application
    Filed: April 24, 2013
    Publication date: September 5, 2013
    Applicant: diaDexus, Inc.
    Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
  • Patent number: 8524236
    Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: September 3, 2013
    Assignee: Domantis Limited
    Inventors: Steven Grant, Haiqun Liu, Kevin Moulder
  • Publication number: 20130227747
    Abstract: Described is an antigen-binding protein, preferably comprising an amino acid sequence that comprises four framework regions and three complementarity-determining regions, wherein the antigen-binding protein is capable of binding a chitinous polysaccharide, and uses thereof.
    Type: Application
    Filed: August 26, 2011
    Publication date: August 29, 2013
    Inventors: Peter Verheesen, Chris De Jonghe, Erik Jongedijk
  • Publication number: 20130202622
    Abstract: The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject using immunotherapy to target and eliminate adipocytes.
    Type: Application
    Filed: July 22, 2011
    Publication date: August 8, 2013
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Stanley R. Riddell, Michael Hudecek, Christoph Rader
  • Publication number: 20130195761
    Abstract: Compositions comprising antibodies raised against CAP37 and isoforms thereof, along with antigen binding fragments thereof, are disclosed. These compositions have many uses, such as in detection of CAP37 and as an early detection marker for various disease conditions. In addition, the compositions may be used therapeutically to inhibit, mitigate, or modulate certain cellular activities involving CAP37 or to monitor a disease progression or the success of a disease treatment.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 1, 2013
    Applicant: The Board of Regents of the University of Oklahoma
    Inventors: Heloise Anne Pereira, Melva L. Gonzalez
  • Publication number: 20130183278
    Abstract: The present invention relates to method of identifying whether or not an individual has Parkinson's disease (PD). In particular, the invention relates to a method for identifying whether or not an individual has PD as opposed to another neurodegenerative disease. The method of the invention comprises measuring the concentration of ?-synuclein (?-syn) and the concentration of unphosphorylated tau (tau) and/or phosphorylated tau (p-tau) in a cerebrospinal fluid sample taken from an individual. The method also comprises calculating the ratio of the concentration of tau and/or p-tau to the concentration of ?-syn, and thereby determining whether or not the individual has PD.
    Type: Application
    Filed: July 6, 2011
    Publication date: July 18, 2013
    Applicant: United Arab Emirates University
    Inventors: Omar El-Agnaf, Lucilla Parnetti, Paolo Calabresi
  • Patent number: 8486657
    Abstract: It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: July 16, 2013
    Inventors: Xiaohong Cai, Thomas Cai
  • Publication number: 20130171170
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Application
    Filed: June 12, 2012
    Publication date: July 4, 2013
    Applicant: GENENTECH, INC.
    Inventors: ALLEN J. EBENS, JR., ALANE M. GRAY, WEI-CHING LIANG, YAN WU, SHANG-FAN YU
  • Publication number: 20130164299
    Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.
    Type: Application
    Filed: June 28, 2011
    Publication date: June 27, 2013
    Applicant: C.N.R.S.
    Inventors: Petrus Johannes Louis Spee, Peter Andreas Nicolai Reumert Wagtmann, Stefan Zahn, Elisabeth D. Galsgaard, Birgitte Friedrichsen, Véronique Braud
  • Patent number: 8470991
    Abstract: The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies may be coupled to a therapeutic agent and used in the treatment of cancer.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: June 25, 2013
    Assignee: Merck Patent GmbH
    Inventors: Stephen D. Gillies, Kin-Ming Lo, Susan Xiuqi Qian
  • Patent number: 8466261
    Abstract: Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: June 18, 2013
    Assignee: Immunomedics, Inc.
    Inventor: Hans J. Hansen
  • Publication number: 20130142813
    Abstract: In order to identify a factor demonstrating a repellent effect on axon extension of a neuron, lysophosphatidylglucoside (LPG) has been found to have an activity as a chemorepellent effect on axon guidance of a DRG sensory neuron specific to a neuron expressing TrkA, an NGF receptor. In addition, it has been found out that suppressing the function of LPG makes it possible to suppress a repellent effect of LPG on axon extension of a neuron expressing TrkA. A molecule capable of suppressing the function of LPG can be a composition promoting repairing of a neural circuit in neuronal damages and the like.
    Type: Application
    Filed: July 7, 2011
    Publication date: June 6, 2013
    Applicant: RIKEN
    Inventors: Yoshio Hirabayashi, Hiroyuki Kamiguchi, Kunihiro Ohta, Akiho Nakamura
  • Patent number: 8455627
    Abstract: The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: June 4, 2013
    Assignee: Affimed Therapeutics, AG
    Inventors: Claudia Linhard, Stefan Knackmuss, Melvyn Little, Karlheinz Peter, Peter Roettgen, Meike Schwarz
  • Publication number: 20130137096
    Abstract: The Invention relates to an ex vivo method of diagnosing or predicting a hereditary spastic paraplegias (HSP), in a subject, which method comprises detecting a mutation in the ZFYVE26 gene or protein (spastizin), wherein said mutation is indicative of a hereditary spastic paraplegias (HSP).
    Type: Application
    Filed: October 31, 2012
    Publication date: May 30, 2013
    Applicant: Institut National de la Sante et de la Recherche Medical (INSERM)
    Inventor: Institut National de la Sante et de la Recherche
  • Publication number: 20130129728
    Abstract: The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both.
    Type: Application
    Filed: June 22, 2011
    Publication date: May 23, 2013
    Applicant: The Regents of the University of Colorado, a Body Corporate
    Inventors: V. Michael Holers, Joshua M. Thurman, Liudmila Kulik
  • Publication number: 20130122002
    Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.
    Type: Application
    Filed: July 22, 2011
    Publication date: May 16, 2013
    Applicant: Insitutut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Eric Rubinstein, Céline Greco, François Le Naour, Claude Boucheix
  • Publication number: 20130122052
    Abstract: The invention relates to the field of immunologically reactive molecules used to improve implantable medical devices. Immobilization of selected antibody molecules onto the surface of medical implants enable localization and concentration of in vivo growth factors in a timely manner to enhance the wound healing process following implantation of the device. When in vivo BMP-2 growth factor was captured on an implant device by attached monoclonal antibodies, the biological activity of BMP-2 was enhanced in the vicinity of the implant device. BMP-2 growth factor-specific antibody molecules or their fragments when immobilized on titanium dental or orthopedic implants improve osseo-integration.
    Type: Application
    Filed: January 20, 2010
    Publication date: May 16, 2013
    Inventor: Homayoun H. Zadeh
  • Publication number: 20130115227
    Abstract: Disclosed are antibodies that bind amyloid beta-derived diffusible ligands, also known as ADDLs. The antibodies are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs.
    Type: Application
    Filed: July 13, 2011
    Publication date: May 9, 2013
    Inventors: Renee C. Gaspar, Paul J. Shughrue, Fubao Wang, Weirong Wang, Ningyan Zhang, Wei-Qin Zhao, Min Xu, Alexander McCampbell
  • Patent number: 8435524
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: May 7, 2013
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Publication number: 20130109593
    Abstract: The present invention is related to a system for the heterologous expression of a monoclonal Antibody (mAb) or a fragment or derivative thereof, said system comprising at least one ciliate host cell, and incorporated, into said ciliate host cell, at least one heterologous nucleic acid molecule encoding for said monoclonal Antibody, or a fragment or derivative thereof.
    Type: Application
    Filed: March 2, 2011
    Publication date: May 2, 2013
    Applicant: CILIAN AG
    Inventors: Marcus Hartmann, Jenny Apelt
  • Publication number: 20130101606
    Abstract: This invention relates to novel phosphorylation sites in cardiac Troponin I that are associated with the onset of heart failure. The phosphorylation sites, i.e., serine 5, tyrosine 26, threonine 51, serine 166, threonine 181 and/or serine 199, can be used as biomarkers for (i) identifying subjects at risk for the development of heart failure, (ii) treating subjects having a higher than normal level of the biomarker, and (iii) monitoring therapy of a subject at risk for the development of heart failure. Also described are antibodies, reagents, and kits for carrying out a method of the present invention.
    Type: Application
    Filed: February 17, 2011
    Publication date: April 25, 2013
    Applicants: VU-VUMC IP MANAGEMENT BV, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Pingbo Zhang, Jennifer E. Van Eyk, Anne M. Murphy, Ger Stienen, Jolanda van der Velden, Viola Kooij
  • Publication number: 20130095116
    Abstract: The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: July 13, 2012
    Publication date: April 18, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Fumiko Takada Axelrod, Timothy Charles Hoey, Cecile Chartier-Courtaud
  • Patent number: 8404807
    Abstract: TSG101 is a tumor susceptibility gene whose homozygous functional knock out in fibroblasts leads to transformation and the ability of these cells to form metastatic tumors in nude mice. The cellular transformation that results from inactivation of TSG101 is reversible by restoration of TSG101 function. Decreased expression of TSG101 is associated with the occurrence of certain human cancers, including breast carcinomas. The TSG101 nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: March 26, 2013
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stanley N. Cohen, Limin Li
  • Patent number: 8398981
    Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: March 19, 2013
    Assignees: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Takeshi Iwatsubo, Tatsuhiko Kodama, Takao Hamakubo, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
  • Publication number: 20130064836
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Application
    Filed: July 25, 2012
    Publication date: March 14, 2013
    Inventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
  • Patent number: 8394931
    Abstract: This invention concerns a panel of monoclonal antibodies against the High Mobility Group A 1 protein (HMGA1) and a process for preparing them, as well as the use of said antibodies for the quantitative determination of HMGA1 in biological fluids or in protein Iy sates deriving from lymphocyte cells. This invention also concerns a diagnostic kit for assessing risk factors related to the expression of the HMGA1 proteins.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: March 12, 2013
    Assignee: Areta International S.R.L.
    Inventors: Alfredo Fusco, Antonio Orlandi, Maria Luisa Nolli
  • Publication number: 20130058956
    Abstract: The present invention relates to the inhibition of the circulating extracellular form of the interferon inducible protein 16 (extracellular IFI16) for the treatment of diseases, particularly autoimmune and/or inflammatory disorders or infective disorders.
    Type: Application
    Filed: January 28, 2011
    Publication date: March 7, 2013
    Applicant: Universita degli Studi del Piemonte Orientale "A Avogedro" (University of Piemonte Orientale)
    Inventors: Michele Mondini, Silvia Costa, Marisa Gariglio, Santo Landolfo
  • Publication number: 20130058868
    Abstract: The present invention relates generally to binding agents useful in the selective depletion of T cells in vivo. More specifically, the invention relates to ICOS-binding agents which once bound to ICOS expressed on the surface of cells, in particular ICOS-bearing activated T cells, result in the in vivo depletion of cells to which they are bound. Methods of treating T cell related diseases using said ICOS-binding agents, and pharmaceutical compositions comprising said ICOS-binding agents, a method of identifying an ICOS-binding agent, and monoclonal anti-ICOS antibodies capable of eliminating cells in vivo which express ICOS on their surface are also provided.
    Type: Application
    Filed: October 22, 2012
    Publication date: March 7, 2013
    Applicant: Bundesrepublik Deutschland letztvertreten durch das Robert- Koch-lnstitut vertreten durch seinen
    Inventor: Bundesrepublik Deutschland letztvertreten durch
  • Patent number: 8389688
    Abstract: The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework regions of the immunoglobulin light chain variable region (“VK”). The invention further comprises heavy and/or light chain FW regions that contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. Human or humanized VH framework regions of antibodies of the invention may comprise one or more of the following residues: a valine (V) at position 24 of framework region 1, a glycine (G) at position 49 of framework region 2, and an asparagine (N) at position 73 of framework region 3, numbered according to Kabat.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: March 5, 2013
    Assignee: Aeres Biomedical, Ltd.
    Inventors: Tarran Jones, David G. Williams
  • Patent number: 8389224
    Abstract: Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: March 5, 2013
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Norman B. Purvis, Gregory T. Stelzer
  • Patent number: 8388971
    Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: March 5, 2013
    Assignees: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Vahe Bedian, Ronald P. Gladue, Jose Ramon Corvalan, Xiao-Chi Jia, Xiao Feng
  • Patent number: RE44389
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: July 23, 2013
    Assignee: Hoffman-La Roche Inc.
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Braemer, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt